Skip to main content
Scott C. Woller

Scott C. Woller, MD

Languages spoken: English, Spanish, Portuguese

Academic Information

Departments Primary - Internal Medicine

Divisions: General Medicine

Board Certification

  • American Board of Internal Medicine (Internal Medicine)

Research Interests

  • Venous Thrombosis
  • Antithrombotic Therapy

Dr. Woller’s academic interests reside in thrombosis medicine and anticoagulation management. With a particular interest in the prevention of venous thromboembolic disease, Dr. Woller has served as investigator on multiple ongoing and completed clinical trials including the NIH-funded studies (COAG, GIFT) serving as site PI for GIFT. Dr. Woller is Co-Chair for the American College of Chest Physicians (ACCP) Clinical Practice Guideline that addresses antithrombotic therapy for venous thromboembolic disease, and as was a panelist for the Vascular Access Appropriateness Panel housed at the University of Michigan. Dr. Woller is an invited panelist for the Centers for Disease Control and Prevention (CDC) Risk Assessment Model for the Prevention of Venous Thromboembolic Disease in Medical Patients program.

Dr. Woller is Professor of Medicine, University of Utah School of Medicine, Professor in Research, Intermountain Healthcare, and is a recognized teacher and recipient of the Intermountain Medical Center Housestaff Teaching Award (2011), the University of Utah School of Medicine Outstanding Faculty Teaching Award (2012), and the University of Utah Department of Internal Medicine Outstanding Faculty Subspecialty Teaching Award (2021). Dr. Woller, Fellow of the American College of Chest Physicians (FCCP) and Fellow of the American College of Physicians (FACP), is Utah Chapter Governor of the American College of Physicians (Class of 2025). Dr. Woller's research group was awarded the 2015 U.S. Centers for Disease Control and Prevention (CDC) Healthcare-Associated Venous Thromboembolism (HA-VTE) Prevention Challenge Award.

Dr. Woller received his medical degree from Northwestern University Medical School in 2000. Dr. Woller completed his residency at the University of Utah Hospital (2003) then served as Chief Medical Resident in 2003-04. Dr. Woller is Board Certified in Internal Medicine and attends at the Intermountain Medical Center, Murray UT where he serves as Chair of Medicine.

Education History

Chief Resident University of Utah School of Medicine
Chief Resident
University of Utah School of Medicine
Resident
Internship University of Utah School of Medicine
Intern
Northwestern University Medical School
MD
Undergraduate University of Wisconsin - Milwaukee
BS

Selected Publications

Journal Article

  1. Woller SC, Stevens SM, Bledsoe JR, Hellewell J, Kraft A, Butler AM, Fazili M, Lloyd JF, Christensen PS, Peltan ID, Barnes GD, Horne BD (2024). Methods of a cluster-randomized, type II hybrid implementation effectiveness trial to prospectively assess extended-duration thromboprophylaxis for at-risk medical patients being discharged to prevent hospital-associated venous thromboembolism. Res Pract Thromb Haemost, 8(6), 102549. (Read full article)
  2. Parks AL, Stevens SM, Woller SC (2024). Anticoagulant therapy in renal insufficiency theme: Anticoagulation in complex situations. Thromb Res, 241, 109097. (Read full article)
  3. Groat D, Martin KA, Rosovsky RP, Sanfilippo KM, Gaddh M, Baumann Kreuziger L, Federici E, Woller SC, Venous thromboEmbolism Network US VENUS VTE Treatment and Anticoagulation Management Group (2023). Primary Care Clinicians' Prescribing Patterns of Reduced-Dose Direct Oral Anticoagulants for Extended-Phase Venous Thromboembolism Treatment. J Clin Med, 13(1). (Read full article)
  4. Lee Cervi A, Applegate D, Stevens SM, Woller SC, Baumann Kreuziger LM, Punchhalapalli K, Wang TF, Lecumberri R, Greco K, Bai Y, Bolger S, Fontyn S, Schulman S, Foster G, Douketis JD (2023). Antithrombotic Management of Patients with Deep Vein Thrombosis and Venous Stents: An International Registry. J Thromb Haemost. (Read full article)
  5. Parks AL, Fazili M, Aston V, Porter TF, Branch DW, Woller SC, Snow GL, Stevens SM (2023). Excluding pregnancy-associated deep vein thrombosis with whole-leg ultrasound. Res Pract Thromb Haemost, 7(7), 102202. (Read full article)
  6. Kay AB, Morris DS, Woller SC, Collingridge DS, Majercik S (2023). Below the knee, let it be: Management of calf DVT in hospitalized trauma patients. Am J Surg. (Read full article)
  7. de Jong CMM, de Wit K, Black SA, Gwozdz AM, Masias C, Parks AL, Robert-Ebadi H, Talerico R, Woller SC, Klok FA (2023). Use of patient-reported outcome measures in patients with venous thromboembolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. J Thromb Haemost. (Read full article)
  8. Hyder SN, Han HB, Ash S, Horne BD, Stevens SM, Woller SC, Barnes GD (2023). Predicting post-discharge venous thromboembolism and bleeding among medical patients: External validation of a novel risk score utilizing ubiquitous biomarkers. Thromb Res, 227, 45-50. (Read full article)
  9. Bledsoe J, Woller SC, Brooks M, Sciurba FC, Krishnan JA, Martin D, Hou P, Lin JY, Kindzelski A, Handberg E, Kirwan BA, Zaharris E, Castro L, Shapiro NL, Pepine CJ, Majercik S, Fu Z, Zhong Y, Venugopal V, Lai YH, Ridker PM, Connors JM (2023). Clinically stable covid-19 patients presenting to acute unscheduled episodic care venues have increased risk of hospitalization: secondary analysis of a randomized control trial. BMC Infect Dis, 23(1), 325. (Read full article)
  10. Martin KA, Lancki N, Li C, Eyster ME, Sanfilippo K, Woller IA, Woller SC, Kreuziger LB, Rosovsky RP (2023). DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network. J Thromb Thrombolysis. (Read full article)
  11. Sanchez-Garcia J, Lopez-Verdugo F, LeCorchick S, Tran A, Gilroy RK, Fujita S, Zendejas I, Gagnon A, Dow S, Krong J, Rodriguez-Davalos MI, Stevens SM, Woller SC, Alonso D (2023). Performance of a Prospective Anticoagulation Stratification Algorithm After Liver Transplantation. Transplant Direct, 9(3), e1453. (Read full article)
  12. Khairani CD, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller SC, Cortes-Hernandez J, Connors JM, Kanthi Y, Krumholz HM, Middeldorp S, Falanga A, Cushman M, Goldhaber SZ, Garcia DA, Bikdeli B (2022). Direct Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials. J Am Coll Cardiol, 81, 16-30. (Read full article)
  13. Tesfazghi MT, Bass AR, Al-Hammadi N, Woller SC, Stevens SM, Eby CS, Scott MG, Snyder L, Wildes TS, Gage BF (2022). Predicting Postoperative Troponin in Patients Undergoing Elective Hip or Knee Arthroplasty: A Comparison of Five Cardiac Risk Prediction Tools. Cardiol Res Pract, 2022, 8244047. (Read full article)
  14. Woller IA, Woller SC, Stevens SM, Lloyd JF, Conner KE, Gordon BH, Snow GL, Jones P, Bledsoe JR (2022). Synoptic reporting accuracy for computed tomography pulmonary arteriography among patients suspected of pulmonary embolism. J Am Coll Emerg Physicians Open, 3(5), e12801. (Read full article)
  15. Carmichael HL, Peltan I, Palakanis K, Davis A, Dalto J, Jacobs JR, Rhodes R, Shah M, Webb B, Woller SC, Bledsoe JR (2022). Remote biometric monitoring of COVID-19 patients with exertional hypoxia treated with supplemental oxygen. Chest. (Read full article)
  16. Allen-Brady K, Colletier KJ, Woller S, Eliason K, Uchida AM, Ro G, Newman M, Peterson KA (2022). Eosinophilic Gastritis and Enteritis Are Increased in Families with Eosinophilic Esophagitis. Am J Gastroenterol, 118(2), 263-268. (Read full article)
  17. Bunch TJ, May H, Cutler M, Woller SC, Jacobs V, Stevens SM, Carlquist J, Knowlton KU, Muhlestein JB, Steinberg BA, Anderson JL (2022). Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non-valvular atrial fibrillation (cognitive decline and dementia in patients with non-valvular atrial fibrillation [CAF] trial). J Arrhythm, 38(6), 997-1008. (Read full article)
  18. Woller SC, de Wit K, Robert-Ebadi H, Masias C, Klok FA, den Exter PL, Morange PE, Castelli D, Hansen JB (2022). A systematic review of biomarkers among hospitalized patients with COVID-19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH. Res Pract Thromb Haemost, 6(6), e12786. (Read full article)
  19. Woller SC, Stevens SM, Bledsoe JR, Fazili M, Lloyd JF, Snow GL, Horne BD (2022). Biomarker derived risk scores predict venous thromboembolism and major bleeding among patients with COVID-19. Res Pract Thromb Haemost, 6(5), e12765. (Read full article)
  20. Groat D, Martin KA, Rosovsky RP, Sanfilippo KM, Gaddh M, Kreuziger LB, Eyster ME, Woller SC, Venous thromboEmbolism Network US VENUS VTE Treatment Anticoagulation Management Group (2022). Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment. Res Pract Thromb Haemost, 6(4), e12740. (Read full article)
  21. den Exter PL, Woller SC, Robert-Ebadi H, Masias C, Morange PE, Castelli D, Hansen JB, Geersing GJ, Siegal DM, de Wit K, Klok FA (2022). Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. J Thromb Haemost, 20, 1910-1919. (Read full article)
  22. Bledsoe JR, Knox D, Peltan ID, Woller SC, Lloyd JF, Snow GL, Horne BD, Connors JM, Kline JA (2022). D-dimer Thresholds to Exclude Pulmonary Embolism among COVID-19 Patients in the Emergency Department: Derivation with Independent Validation. Clin Appl Thromb Hemost, 28, 10760296221117997. (Read full article)
  23. Stevens SM, Fazili M, Woller SC (2020). Choosing ultrasound technique for suspected deep vein thrombosis: Which is best? Quant Imaging Med Surg, 10(6), 1418-1421. (Read full article)
  24. Kay A, Majercik S, Sorensen J, Woller S, Stevens S, White T, Morris D, Baldwin M, Bledsoe J (2018). Weight-based enoxaparin dosing and deep vein thrombosis in hospitalized trauma patients: A double-blind, randomized, pilot study. Surgery, 164(1), 144-149. (Read full article)
  25. Woller SC, Stevens SM, Towner S, Olson J, Christensen P, Hamilton S, Newman L, Mott L, Hu P, Brunisholz KD, Long Y, Lloyd J, Evans RS, Cannon W, Elliott CG (2015). The computerized clinical decision support improves warfarin therapy and reduces recurrent venous thromboembolism. Vasomed, 27(3), 146-148. (Read full article)
  26. Kearon C, Spencer FA, OKeeffe D, Parpia S, Schulman S, Baglin T, Stevens SM, Kaatz S, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Moll S, Connors JM, Ginsberg JS, Spadafora L, Julian JA, Smale S, Winkworth T, Bedek N, Glushchenko A, Gross PL, Linkins LA, ODonnell M, Weitz J, Conway J, Watts M, Bourke D, Kiely P, Baglin C, Rudd-Scott L, Zondag M, Eikelboom J, Aston VT, Elliott G, Woller SC, Ellsworth S, Gikas H, Ahsan ST, Shah V, Mahony M, Rodrigues A, Zwicker JI, Betz R, Schnurr T, Chan H, Crowther M, Lim W, Peters T, Lammer M, Kaboli P, Leaverton S, MacFarlane D, Jacobs H, Abdallah R, Broome C, Key NS, Kasthuri RS, Jeanneret C, Kellerman R, Naik N, Rowe BS, Stewart L, Wentz R, Berliner N, McCaffrey R (2015). D-Dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: A cohort study. Ann Intern Med, 162(1), 27-34. (Read full article)
  27. Geersing GJ, Zuithoff P, Kearon C, Anderson D, Ten Cate-Hoek A, Elf J, Bates S, Hoes A, Kraaijenhagen R, Oudega R, Schutgens R, Stevens S, Woller S, Wells P, Moons K (2014). Exclude DVT with a clinical decision rule. Huisarts Wet, 57(12). (Read full article)
  28. Woller SC, Stevens SM, Jones JP (2012). Erratum: Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients (American Journal of Medicine (2011) 124 (947-954)). Am J Med, 125(10). (Read full article)
  29. Woller SBertin KStevens SJones JEvans RLloyd JSamuelson KHickman JHanseen RBarton SAston VElliott C (2012). A Prospective Comparison of Warfarin to Aspirin for Thromboprophylaxis in Total Hip and Total Knee Arthroplasty. J Arthroplasty, 27(1), 1-9.e2. (Read full article)
  30. Fiore MC, Hartman M, Mielke M, Strecker E, Woller S, Baker T (1996). Raising Wisconsin's tobacco excise fees: Protecting children, increasing revenue, saving lives. Wis Med J, 95(11), 769-772. (Read full article)

Review

  1. Stevens SM, Woller SC, Baumann Kreuziger L, Doerschug K, Geersing GJ, Klok FA, King CS, Murin S, Vintch JRE, Wells PS, Wasan S, Moores LK (2024). Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012-2021. [Review]. Chest. (Read full article)
  2. Woller SC, Stevens SM, Johnson SA, Bledsoe JR, Galovic B, Lloyd JF, Wilson EL, Armbruster B, Evans RS (2019). Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM-DVT): Methods of a prospective single-arm management study. [Review]. Res Pract Thromb Haemost, 3(3), 340-348. (Read full article)

Letter

  1. Martin KA, Lancki N, Kreuziger LB, Li C, Eyster ME, Sanfilippo K, Woller SC, Rosovsky RP (2023). DOAC compared with warfarin for VTE in low weight patients: A retrospective cohort study conducted through the VENUS network. [Letter to the editor]. Thromb Res, 229, 146-148. (Read full article)
  2. Woller S, Stevens S (2012). The reply [Letter to the editor]. Am J Med, 125(11). (Read full article)

Other

  1. Martin KA, Lancki N, Li C, Eyster ME, Sanfilippo K, Woller IA, Woller SC, Kreuziger LB, Rosovsky RP (2023). Correction to: DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network. J Thromb Thrombolysis. Netherlands. (Read full article)